Chitosan reduces inflammation and protects against oxidative stress in a hyperlipidemic rat model: relevance to nonalcoholic fatty liver disease

[1] Younossi ZM(2016)Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes Hepatology 64 73-84

[2] Koenig AB(2018)The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases Hepatology 67 328-357

[3] Abdelatif D(2020)New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis Pharmacol Rep 72 1-12

[4] Chalasani N(2017)Non-alcoholic fatty liver disease: an expanded review World J Hepatol 9 715-732

[5] Younossi Z(2010)Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications Hepatology 51 679-689

[6] Lavine JE(2011)Nonalcoholic fatty liver disease: focus on lipoprotein and lipid deregulation J Lipids 2011 1-14

[7] Pydyn N(2019)Statin toxicity Circ Res 124 328-350

[8] Miękus K(2020)Herbal drug discovery for the treatment of nonalcoholic fatty liver disease Acta Pharm Sin B 10 3-18

[9] Jura J(2010)N-Acetylglucosamine: production and applications Mar Drugs 8 2493-2516

[10] Kotlinowski J(2021)Chitosan displays a potent caloric restriction mimetic effect in senescent rats Rejuvenation Res 21 92-630

[1] Younossi ZM(2016)Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes Hepatology 64 73-84

[2] Koenig AB(2018)The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases Hepatology 67 328-357

[3] Abdelatif D(2020)New therapeutic strategies in nonalcoholic fatty liver disease: a focus on promising drugs for nonalcoholic steatohepatitis Pharmacol Rep 72 1-12

[4] Chalasani N(2017)Non-alcoholic fatty liver disease: an expanded review World J Hepatol 9 715-732

[5] Younossi Z(2010)Obesity and nonalcoholic fatty liver disease: Biochemical, metabolic, and clinical implications Hepatology 51 679-689

[6] Lavine JE(2011)Nonalcoholic fatty liver disease: focus on lipoprotein and lipid deregulation J Lipids 2011 1-14

[7] Pydyn N(2019)Statin toxicity Circ Res 124 328-350

[8] Miękus K(2020)Herbal drug discovery for the treatment of nonalcoholic fatty liver disease Acta Pharm Sin B 10 3-18

[9] Jura J(2010)N-Acetylglucosamine: production and applications Mar Drugs 8 2493-2516

[10] Kotlinowski J(2021)Chitosan displays a potent caloric restriction mimetic effect in senescent rats Rejuvenation Res 21 92-630